Jasper Therapeutics, Inc. - *W EXP 09/24/202 (JSPRW)

CUSIP: 471871111

Q2 2026 13F Holders as of 30 Jun 2026

Share change
-27,700
SEC-reported price per share
$0.01
Number of holders
7
Value change
-$611
Number of buys
1
Number of sells
2

Security key

471871111

Report period

Q2 2026

Institutions

7

Top holders

7

Ownership snapshot

Top reported holders of JSPRW - Jasper Therapeutics, Inc. - *W EXP 09/24/202 (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
T. Rowe Price Investment ...
Disclosed value leader
Velan Capital Investment ...
Comparable rows
10/15
Latest evidence
30 Jun 2026
13D/G 13F 3/4/5 Lead comparable stake: 7.1% 5 rows are not safely comparable across share classes. 13D/G row: T. Rowe Price Investment Management, Inc. Showing 1-6 of 15 holder rows.

Quick read

T. Rowe Price Investment Management, Inc. leads the comparable SEC ownership view at 7.1%.

10 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens T. Rowe Price Investment Management, Inc.'s linked filing trail.
Comparable ownership Top 5
T. Rowe Price Investment Manageme... 7.1%
ACORN BIOVENTURES, L.P. 5.3%
MORGAN STANLEY 4.8%
KINGDON CAPITAL MANAGEMENT, L.L.C. 4.7%
Carlyle Group Inc. 3.8%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
T. Rowe Price Investment Management, Inc.
13D/G
7.1%
Reported 13D/G · 30 Sep 2025
$4,897,117
2,057,612 shares
$0 30 Sep 2025
ACORN BIOVENTURES, L.P.
13D/G
Anders Hove
5.3%
Reported 13D/G · 23 Jan 2026
$2,660,821
1,486,492 shares
-$537,000 23 Jan 2026
MORGAN STANLEY
13D/G 13F
Company
4.8%
Reported 13D/G · 31 Mar 2026
$1,226,746
1,333,420 shares
-$585,456 31 Mar 2026
KINGDON CAPITAL MANAGEMENT, L.L.C.
13D/G 13F
Company
4.7%
Reported 13D/G · 30 Sep 2025
$3,153,131
1,324,845 shares
+$1,332,431 30 Sep 2025
Carlyle Group Inc.
3/4/5 13D/G 13F
Former 10% Owner · The Carlyle Group Inc. · Company
3.8%
Reported 13D/G · 18 Feb 2026
$13,807,148
1,066,189 shares
— 08 Feb 2024
Qiming U.S. Healthcare Fund II, L.P.
3/4/5 13D/G
10%+ Owner
3.3%
Reported 13D/G · 30 Sep 2025
$5,525,844
8,519,648 shares
— 27 Jan 2023
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
7
Shares
2,986,759
Rows available
7
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2026 vs Q1 2026 Across Filers

Q1 2026 holders
8
Q2 2026 holders
7
Holder diff
-1
Investor Q1 2026 Shares Q2 2026 Shares Share Diff Share Chg % Q1 2026 value Q2 2026 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .